Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M. Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse, Solange Peters
Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.
Article
Pharmacology & Pharmacy
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Chongqing Tan
Summary: The study suggests that nivolumab plus ipilimumab may be more cost-effective compared to chemotherapy, especially at a WTP threshold of $100,000/QALY to $150,000/QALY. Body weight and overall survival hazard ratio are key variables influencing the cost-effectiveness ratio.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xuezhi Hao, Aizong Shen, Bin Wu
Summary: The cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small cell lung cancer showed that it is a cost-effective option in the United States but not in China. Sensitivity analyses confirmed the robustness of the results.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Beung-Chul Ahn, Charny Park, Sang-Jin Lee, Sehwa Hong, Ji-Eun Hwang, Kyoungsuk Kwon, Jin Young Kim, Kyung-Hee Kim, Hyae Young Kim, Geon Kook Lee, Youngjoo Lee, Ji-Youn Han
Summary: This study investigated the efficacy of cyclophosphamide and adriamycin induction therapy prior to nivolumab in previously treated non-squamous non-small-cell lung cancer patients with low PD-L1 expression. It was found that the induction therapy reduced myeloid-derived suppressor cells and resulted in a durable response. Additionally, higher baseline levels of transferrin receptor protein predicted a favorable response to nivolumab in patients with low PD-L1 expression.
Article
Oncology
Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, Carolyn J. Presley, Cary P. Gross
Summary: The introduction of immune checkpoint inhibitors has transformed the care of advanced non-small cell lung cancer, but it is unclear how outcomes have changed in clinical practice.
Article
Cell Biology
Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna, Young Hak Kim, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Tomoko Hirano, Fumihiko Matsuda, Toyohiro Hirai, Kazuto Nishio, Takuro Sakagami, Masanori Fukushima, Yoichi Nakanishi, Tasuku Honjo, Isamu Okamoto
Summary: Researchers conducted a clinical trial of bezafibrate in combination with nivolumab for advanced non-small cell lung cancer patients. The combination therapy was well tolerated and showed potential in promoting T cell function and extending the duration of response. This T cell metabolism-targeting combination strategy may have implications for maintaining the antitumor activity of immune checkpoint inhibitors and requires further validation.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Michael Boyer, Mehmet A. N. Sendur, Delvys Rodriguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran Fulden Yumuk, Francisco J. Orlandi, Ticiana A. Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck
Summary: The study showed that adding ipilimumab to pembrolizumab did not improve efficacy and was associated with greater toxicity in metastatic NSCLC patients.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Article
Oncology
Jeffrey M. Clarke, Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara, D. Ross Camidge, Martin Dunbar, Silpa Nuthalapati, Minh H. Dinh, Bruce A. Bach
Summary: The study demonstrated the tolerability and efficacy of the quadruple combination therapy of veliparib with nivolumab and platinum doublet chemotherapy in patients with advanced/metastatic NSCLC with promising antitumor activity. This four-drug therapy showed no evidence of drug-drug interaction and could be a potential treatment option for NSCLC patients.
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Guangxian Meng, Xiaowei Liu, Tian Ma, Desheng Lv, Ge Sun
Summary: This meta-analysis demonstrates that high-TMB NSCLC patients treated with immunotherapy have more clinical benefits in terms of treatment response and survival outcomes. TMB is a promising biomarker for selecting NSCLC patients who can benefit more from immunotherapy.
Article
Medicine, General & Internal
Kenneth L. Kehl, Scott Greenwald, Nassib G. Chamoun, Paul J. Manberg, Deborah Schrag
Summary: This study investigated treatment patterns and overall survival associated with immunotherapy, chemotherapy, and chemoimmunotherapy in older patients with advanced NSCLC and Medicare coverage. Results showed a rapid uptake of immunotherapy among Medicare-insured patients, but survival estimates were shorter than those reported in registrational trials.
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Letter
Medicine, General & Internal
Tawee Tanvetyanon
Summary: This article reports that neoadjuvant treatment with nivolumab does not impede the feasibility of lung cancer surgery, but some patients had their surgeries canceled due to disease progression after treatment, which is concerning as they could have been cured through surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Hanae Ida, Yasushi Goto, Jun Sato, Shintaro Kanda, Yuki Shinno, Ryou Morita, Shuji Murakami, Yuji Matsumoto, Tatsuya Yoshida, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Takahiro Fukuda, Ken Ohashi, Yuichiro Ohe
Article
Oncology
Toshihiko Doi, Yutaka Fujiwara, Takafumi Koyama, Masafumi Ikeda, Christoph Helwig, Morihiro Watanabe, Yulia Vugmeyster, Masatoshi Kudo
Article
Oncology
Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, Toshio Shimizu, Kan Yonemori, Nobuaki Matsubara, Izumi Ohno, Takahiro Kogawa, Yoichi Naito, Lance Leopold, Mihaela Munteanu, Naoyoshi Yatsuzuka, Shi Rong Han, Ayman Samkari, Noboru Yamamoto
Summary: The open-label, phase I KEYNOTE-434 study evaluated the safety and tolerability of epacadostat alone and in combination with pembrolizumab in Japanese patients with advanced solid tumors. Results showed that the combination therapy was generally safe and well tolerated, with potential therapeutic benefits for this patient population.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Oncology
Nobumasa Tamura, Yutaka Fujiwara, Taiki Hashimoto, Hideaki Shiraishi, Shigehisa Kitano, Toshio Shimizu, Kazuyoshi Kuwano, Noboru Yamamoto, Noriko Motoi
Article
Oncology
Kazumi Nishino, Yutaka Fujiwara, Yuichiro Ohe, Ryota Saito, Eisaku Miyauchi, Tetsu Kobayashi, Yasuo Nakai, Toshiaki Takahashi, Taro Shibata, Tetsuya Hamaguchi, Katsuko Kikuchi, Naoya Yamazaki, Haruhiko Fukuda, Keiko Nozawa, Yoshio Kiyohara
Summary: The study aimed to compare the efficacy of reactive topical corticosteroid strategies employing serially ranking-DOWN from very strong steroid levels with strategies employing serially ranking-UP from weak steroid levels in treating facial acneiform rash induced by EGFRIs. The results show that in NSCLC patients receiving EGFRIs, preemptive therapy of oral minocycline and heparinoid moisturizer can reduce the incidence of facial acneiform rash.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto
Summary: TAS0313, a novel cancer vaccine cocktail targeting multiple cancer antigens, was evaluated in Japanese patients with advanced solid tumors, showing safety, tolerability, and induction of immune responses. While some patients had stable disease and increased TILs, further research is needed to understand the impact of TILs on efficacy.
Article
Oncology
Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano, Toshio Shimizu, Junichi Tomomatsu, Takafumi Koyama, Mariko Ogura, Masaya Tachibana, Yasuyuki Kakurai, Tomonari Yamashita, Sakura Sakajiri, Noboru Yamamoto
Summary: Milademetan is an orally available MDM2 antagonist that increases p53 activity by disrupting the MDM2-p53 interaction, showing potential antineoplastic activity. In a study with Japanese patients with solid tumors, Milademetan demonstrated good tolerability and moderate antitumor activity. The recommended dose for Phase II was determined to be 90 mg in a once-daily 21/28-day schedule.
Article
Oncology
Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Sumiko Okubo, Kazuteru Fukasawa, Haruyasu Murakami
Summary: Telisotuzumab vedotin demonstrated manageable safety profile and antitumor activity in Japanese patients with advanced solid tumors, with the recommended phase 2 dose confirmed as 2.7 mg/kg every 3 weeks.
Article
Oncology
Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto
Summary: MORAb-202, an antibody-drug conjugate targeting FR alpha-positive solid tumors, showed promising antitumor activity and generally good tolerability in the first-in-human study, indicating the need for further investigations to establish appropriate dosage and clinical utility.
CLINICAL CANCER RESEARCH
(2021)
Letter
Dermatology
Mao Okumura, Eiji Nakano, Kenjiro Namikawa, Akira Takahashi, Yutaka Fujiwara, Naoya Yamazaki
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2022)
Article
Oncology
Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto
Summary: This study reports the dose-escalation part of a phase I study of liposomal eribulin in Japanese patients with advanced solid tumors. The study found that liposomal eribulin was well tolerated at a dosage of 2.0 mg/m(2) once every three weeks and 1.5 mg/m(2) once every two weeks, and recommended a dosage of 2.0 mg/m(2) once every three weeks.
CLINICAL CANCER RESEARCH
(2022)
Article
Respiratory System
Yoshitsugu Horio, Hiroyuki Tachibana, Junichi Shimizu, Waki Hosoda, Yutaka Fujiwara
Summary: This is a case report of successful treatment for ES-SCLC, where the patient achieved a long period of recurrence-free survival through a combination of induction chemotherapy, chemoradiotherapy, and additional chemotherapy.
RESPIROLOGY CASE REPORTS
(2022)
Article
Oncology
Yutaka Fujiwara, Yasuo Takahashi, Morihito Okada, Takumi Kishimoto, Shunsuke Kondo, Koshi Fujikawa, Manabu Hayama, Masatoshi Sugeno, Shinya Ueda, Keiko Komuro, Mark Lanasa, Takashi Nakano
Summary: This phase I trial demonstrates that tremelimumab monotherapy and combination therapy with durvalumab are safe and tolerable for Japanese patients with advanced cancer.
Article
Oncology
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
Summary: This study evaluated the efficacy and safety of ONO-4578 as monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors. The results showed that ONO-4578 was well tolerated at the tested doses and showed signs of antitumor activity.
Article
Oncology
Yutaka Fujiwara, Reiko Makihara, Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito, Yukari Tsubata, Takae Okuno, Toshiaki Takahashi, Haruki Kobayashi, Yuki Shinno, Yoshitaka Zenke, Takaya Ikeda, Yukio Hosomi, Kageaki Watanabe, Satoru Kitazono, Naomi Sakiyama, Yoshinori Makino, Noboru Yamamoto
Summary: This study aimed to investigate the safety, pharmacokinetics (PK), and recommended dose (RD) of osimertinib in NSCLC patients with impaired renal function and low body weight. The PK parameters were found to be similar in patients with normal renal function and body weight. However, toxicity was more frequent in patients with impaired renal function and low body weight. Clinicians should exercise caution when prescribing osimertinib in NSCLC patients with impaired renal function and low body weight.